Is Antithrombin Deficiency Worse Than Factor V Leiden?
At a Glance
Antithrombin deficiency is considered significantly more severe than the common form of Factor V Leiden. Without antithrombin, the body lacks its primary "brake" to stop blood clots, leading to a much higher lifetime risk of dangerous clots and requiring specialized, long-term blood thinners.
In this answer
3 sections
Yes, your doctor is correct. Antithrombin deficiency is medically considered a significantly more severe and high-risk blood clotting disorder (thrombophilia) than the most common form of Factor V Leiden [1][2][3].
(Note: When doctors refer to Factor V Leiden being less severe, they are usually talking about the “heterozygous” form, where a person inherits only one copy of the mutated gene. This is by far the most common type.)
To understand why your condition requires stricter management, it helps to compare how these two conditions affect your body’s ability to control blood clotting.
The “Brakes” vs. The “Accelerator”
Your body relies on a delicate balance of proteins to form blood clots when you are bleeding and to stop them from growing out of control.
Antithrombin is the main “brake”
Antithrombin is one of the most important natural anticoagulants in your blood [4][5]. Its primary job is to act as the master “brake” on the clotting process by neutralizing key clotting enzymes (like thrombin and Factor Xa) [4]. When you have antithrombin deficiency, this crucial braking system is either missing or broken. Without a functioning brake, your body’s clotting system can run unchecked, making it easier for clots to form and grow [4][5].
Factor V Leiden is a stuck “accelerator”
In contrast, Factor V Leiden is a mutation that affects one specific protein (Factor V) involved in the chain reaction that builds a clot [5]. Because of a tiny genetic change, this protein resists being turned off by the body’s secondary regulatory systems [4][5]. It acts like a gas pedal that sticks slightly. However, in people with Factor V Leiden, the master “brake” (antithrombin) still functions perfectly, keeping the overall risk much lower [5].
What This Means for Your Health
Because missing the master brake has a more profound effect on the body than a slightly sticky accelerator, antithrombin deficiency carries a much higher clinical risk [4][5].
Much Higher Lifetime Clotting Risk
Without treatment, people with antithrombin deficiency face an estimated 50% to 90% lifetime risk of developing a dangerous blood clot, such as a Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) [6]. This is vastly higher than the low-to-moderate risk seen in people with the most common form of Factor V Leiden [7][8][9].
Important Reassurance: It is vital to know that this high 50% to 90% risk applies to untreated individuals. Working closely with your hematologist and following a prescribed blood thinner regimen dramatically reduces your risk of experiencing a clot.
For those who are not on preventative medication, clots in antithrombin deficiency tend to:
- Happen younger: The first clot often occurs at a younger age [7][6].
- Occur without warning: They frequently happen “unprovoked,” meaning they develop without a clear trigger like surgery or long travel [7][6].
- Be more serious: They carry a higher risk for serious blood clots in the lungs (pulmonary embolisms) [10][11][12], or clots in unusual places like the arteries or veins of the abdomen [13]. Adding external risk factors—such as taking estrogen-containing birth control or hormone replacement therapy—compounds these risks significantly for both conditions, but is especially dangerous without a functioning “brake.”
Higher Risks During Pregnancy
Pregnancy naturally increases the risk of blood clots for anyone. However, the untreated risk for a woman with antithrombin deficiency during pregnancy or shortly after birth is approximately 6.0% to 9.0%, compared to roughly 0.4% to 0.7% for women with the standard Factor V Leiden mutation [14][6]. Managing this requires highly specialized care from a hematologist and an obstetrician [15][16].
Differences in Treatment
The severity of antithrombin deficiency dictates a different approach to treatment:
- Long-Term Blood Thinners: Because the risk of recurrent (repeat) blood clots is high, patients with antithrombin deficiency who have had a clot are frequently placed on lifelong or long-term anticoagulants (blood thinners) [8][17][16]. Many Factor V Leiden patients only need blood thinners temporarily after a clot [2][17].
- Specialized Medications: Standard blood thinners like heparin actually require antithrombin to work properly in your body. Since your antithrombin levels are low, standard heparin may not be fully effective for you [18]. Your doctor may need to prescribe direct oral anticoagulants (DOACs like apixaban/Eliquis or rivaroxaban/Xarelto), which bypass antithrombin [18][19][20], or give you intravenous antithrombin concentrates during high-risk scenarios like surgery or childbirth [15][21][22].
Common questions in this guide
Why is antithrombin deficiency more dangerous than Factor V Leiden?
Why might standard heparin not work for my blood clots?
Should I wear a medical alert bracelet for antithrombin deficiency?
What is the risk of a blood clot with antithrombin deficiency during pregnancy?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given my specific history and antithrombin levels, what is my personal risk of developing a clot while on my current medication?
- 2.Should I be wearing a medical alert bracelet that specifies I have antithrombin deficiency and may not respond to standard heparin in an emergency?
- 3.If I need surgery or become pregnant, exactly how will my care team manage the fact that I might need antithrombin concentrates or specialized bridging therapies?
- 4.Since this is a hereditary condition with a high risk profile, which of my blood relatives should be tested, and at what age should they be screened?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (22)
- 1
Primary and secondary thrombophiliа: pathogenesis, clinical presentation, approaches to thrombotic complications prevention and treatment.
Bereziuk OM, Mazur JV, Berko GK, et al.
Wiadomosci lekarskie (Warsaw, Poland : 1960) 2019; (72(5 cz 1)):908-913.
PMID: 31175794 - 2
Impact of thrombophilia on venous thromboembolism management.
Emmerich J, Zuily S, Gouin-Thibault I, et al.
Presse medicale (Paris, France : 1983) 2024; (53(4)):104247 doi:10.1016/j.lpm.2024.104247.
PMID: 39244017 - 3
Venous thromboembolism risk in adults with hereditary thrombophilia: a systematic review and meta-analysis.
Alnor AB, Gils C, Vinholt PJ
Annals of hematology 2024; (103(10)):4285-4294 doi:10.1007/s00277-024-05926-2.
PMID: 39167180 - 4
Management of antithrombin deficiency: an update for clinicians.
Bravo-Pérez C, Vicente V, Corral J
Expert review of hematology 2019; (12(6)):397-405 doi:10.1080/17474086.2019.1611424.
PMID: 31116611 - 5
A review of laboratory considerations in thrombophilia testing.
Ong J, Bennett A
Pathology 2022; (54(7)):835-841 doi:10.1016/j.pathol.2022.09.001.
PMID: 36241557 - 6
Management of Venous Thromboembolism in Patients with Hereditary Antithrombin Deficiency and Pregnancy: Case Report and Review of the Literature.
Refaei M, Xing L, Lim W, et al.
Case reports in hematology 2017; (2017()):9261351 doi:10.1155/2017/9261351.
PMID: 28168066 - 7
Inherited Thrombophilia in the Era of Direct Oral Anticoagulants.
Khider L, Gendron N, Mauge L
International journal of molecular sciences 2022; (23(3)) doi:10.3390/ijms23031821.
PMID: 35163742 - 8
High risk of thrombosis recurrence in patients with homozygous and compound heterozygous factor V R506Q (Factor V Leiden) and prothrombin G20210A.
Federici EH, Al-Mondhiry H
Thrombosis research 2019; (182()):75-78 doi:10.1016/j.thromres.2019.07.030.
PMID: 31472339 - 9
Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk.
Douxfils J, Morimont L, Bouvy C
Seminars in thrombosis and hemostasis 2020; (46(8)):872-886 doi:10.1055/s-0040-1714140.
PMID: 33080636 - 10
Atypical pulmonary thromboembolism caused by the mutation site SERPINC1 of the antithrombin III gene: A case report.
Lin M, Sun X, Wu J
Medicine 2024; (103(31)):e39175 doi:10.1097/MD.0000000000039175.
PMID: 39093784 - 11
Successful treatment with rivaroxaban of an extended deep vein thrombosis complicated by pulmonary embolism in a patient with familial antithrombin III deficiency: a case report.
Appignani M, Sciartilli A, Caputo M, Di Girolamo E
European heart journal. Case reports 2020; (4(1)):1-5 doi:10.1093/ehjcr/ytz235.
PMID: 32128502 - 12
Cardiac Arrest Due to Pulmonary Embolism After Posterior Spinal Fusion in a Patient With Acute Paraplegia Caused by a Metastatic Spinal Tumor Associated With Congenital Antithrombin III Deficiency.
Funayama T, Tsukanishi T, Noguchi H, et al.
Cureus 2022; (14(2)):e22618 doi:10.7759/cureus.22618.
PMID: 35371744 - 13
Case report: A case of new mutation in SERPINC1 leading to thrombotic microangiopathy.
Li B, Zhang X, Lv H, et al.
Frontiers in genetics 2023; (14()):1278511 doi:10.3389/fgene.2023.1278511.
PMID: 37829283 - 14
Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium.
Gerhardt A, Scharf RE, Greer IA, Zotz RB
Blood 2016; (128(19)):2343-2349 doi:10.1182/blood-2016-03-703728.
PMID: 27613196 - 15
Hereditary antithrombin III deficiency and neuraxial anaesthesia.
Piper BJ, Farrell PT
Anaesthesia and intensive care 2015; (43(6)):782-5 doi:10.1177/0310057X1504300618.
PMID: 26603805 - 16
Issues in the Diagnosis and Management of Hereditary Antithrombin Deficiency.
Bauer KA, Nguyen-Cao TM, Spears JB
The Annals of pharmacotherapy 2016; (50(9)):758-67 doi:10.1177/1060028016651276.
PMID: 27281301 - 17
Antithrombin Deficiency and Thrombosis: A Wide Clinical Scenario Reported in a Single Institution.
Marco-Rico A, Marco-Vera P
Journal of blood medicine 2023; (14()):499-506 doi:10.2147/JBM.S416355.
PMID: 37674759 - 18
The novel SERPINC1 missense mutation c.1148 T > A (p.L383H) causes hereditary antithrombin deficiency and thromboembolism in a Chinese family: a case report.
He F, Wang Y, Ning W, et al.
Journal of medical case reports 2025; (19(1)):102 doi:10.1186/s13256-025-05114-4.
PMID: 40050974 - 19
Successful treatment of a massive pulmonary embolism using rivaroxaban in a patient with antithrombin III deficiency.
Yamaguchi J, Hara N, Yamaguchi T, et al.
Journal of cardiology cases 2017; (16(5)):144-147 doi:10.1016/j.jccase.2017.06.008.
PMID: 30279820 - 20
Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency.
Minami K, Kumagai K, Sugai Y, et al.
Internal medicine (Tokyo, Japan) 2018; (57(14)):2025-2028 doi:10.2169/internalmedicine.0483-17.
PMID: 29526957 - 21
Successful administration of recombinant human antithrombin in a pregnant Japanese woman with hereditary antithrombin deficiency.
Fujibe Y, Mariya T, Mizuuchi M, et al.
Taiwanese journal of obstetrics & gynecology 2019; (58(6)):849-851 doi:10.1016/j.tjog.2019.09.021.
PMID: 31759540 - 22
Risk of pregnancy-related venous thromboembolism and obstetrical complications in women with inherited type I antithrombin deficiency: a retrospective, single-centre, cohort study.
Abbattista M, Gianniello F, Novembrino C, et al.
The Lancet. Haematology 2020; (7(4)):e320-e328 doi:10.1016/S2352-3026(20)30007-7.
PMID: 32112716
This information comparing antithrombin deficiency and Factor V Leiden is for educational purposes only. Always consult your hematologist to evaluate your personal clotting risk and specific treatment needs.
Get notified when new evidence is published on Hereditary thrombophilia due to congenital antithrombin deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.